Encapsulation of selected secondary metabolites on chitosan nanoparticles and evaluation of their in vivo antimycobacterial properties
| dc.contributor.author | Rwegasila, Edward | |
| dc.date.accessioned | 2020-04-20T14:20:13Z | |
| dc.date.available | 2020-04-20T14:20:13Z | |
| dc.date.issued | 2016 | |
| dc.description | Available in print form, East Africana Collection, Dr. Wilbert Chagula Library, Class mark (THS EAF TP248.65.C55R853) | en_US |
| dc.description.abstract | This study investigated the potential of utilizing chitosan nanoparticles (CSNPs) as carrier of antimycobacterial natural products isolated from T. orientalis and E. schliebenii followed by evaluation of their in vivo antimycobacterial properties using Galleria mellonella larvae. The CSNPs were fabricated by the ionic gelation method and characterized by various techniques. The molecular weight of pure chitosan (CS) obtained by deacetylation of chitin was 20.2 kDa as determined by MALD1-TOF-MS. The degree of deactylation (DD) was 73.31% as determined by IR spectroscopy. Scanning Electron Microscopy (SEM) analysis revealed the occurrence of agglomeration in the prepared nanoparticles that were observed at the nanometer scale of 50 to 200 nm. The CS and CSNPs showed thermal stability below 210 oC and 200 oC, respectively. However, the simultaneous thermal analysis (STA) curve of CSNPs loaded with the flavanoid (73) showed a gradual decomposition with the form of free CSNPs observed at 200 oC. The natural products toussaintine A, (72) and 5,7-dihydroxy-3′,4′,5′-trimethoxyisoflavone (73) were effectively encapsulated using CS/TPP ratio of 2:1. The respective encapsulation efficiency and loading capacity of compound 72 were 69.33 and 0.46% while for compound 73 were 70.16 and 0.36%, respectively. The in vitro release study indicated the initial burst of 27 and 42% at the first sixth hours for compound 72 and 73, respectively. The in vivo antimycobacterial evaluation using G. mellonella larvae revealed CSNPs as suitable carriers for improving the efficacy of antimycobacterial natural products by 40 and 60% at the dose of 0.1 µg/ mg bw for compound 72 and 73, respectively. | en_US |
| dc.identifier.citation | Rwegasila, E. (2016) Encapsulation of selected secondary metabolites on chitosan nanoparticles and evaluation of their in vivo antimycobacterial properties, Master dissertation, University of Dar es Salaam, Dar es Salaam | en_US |
| dc.identifier.uri | http://41.86.178.5:8080/xmlui/handle/123456789/9637 | |
| dc.language.iso | en | en_US |
| dc.publisher | University of Dar es Salaam | en_US |
| dc.subject | Chitosan nanoparticles | en_US |
| dc.subject | Chitosan | en_US |
| dc.subject | Chitiri | en_US |
| dc.subject | Grug delivery systems | en_US |
| dc.title | Encapsulation of selected secondary metabolites on chitosan nanoparticles and evaluation of their in vivo antimycobacterial properties | en_US |
| dc.type | Thesis | en_US |